Aripiprazole Long-Acting Injectable for Maintenance Treatment of Bipolar I Disorder in Adults.
Publication/Presentation Date
1-1-2018
Abstract
Bipolar I disorder is a serious and disabling psychiatric illness. It is associated with a significant reduction in quality of life and an increased risk for suicide. Pharmacotherapy is essential for both the acute and maintenance treatment of bi-polar I disorder. While multiple oral medications are recommended for the maintenance treatment, there are not many long-acting injectable medications approved for this indication. New treatments that would improve patient adherence have the potential for decreasing relapses and improving patients' ability to remain functional members of society. In this paper we discuss the available data for safety and efficacy of aripiprazole long-acting injectable in bipolar disorder.
Volume
11
Issue
4
First Page
221
Last Page
223
ISSN
1935-1232
Published In/Presented At
Aggarwal, A., Schrimpf, L., & Lauriello, J. (2018). Aripiprazole Long-Acting Injectable for Maintenance Treatment of Bipolar I Disorder in Adults. Clinical schizophrenia & related psychoses, 11(4), 221–223.
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
29341822
Department(s)
Administration and Leadership
Document Type
Article